Mary Sano

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi request reprint Schizophrenia in a patient with spinocerebellar ataxia 2: coincidence of two disorders or a neurodegenerative disease presenting with psychosis?
    Matthew Rottnek
    Department of Neurology, James J Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA
    Am J Psychiatry 165:964-7. 2008
  2. pmc Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo
    John W Steele
    Departments of Neurology, Psychiatry and Alzheimer s Disease Research Center, Mount Sinai School of Medicine, New York, NY, 10029, USA
    Mol Neurodegener 4:51. 2009
  3. ncbi request reprint Current concepts in the prevention of Alzheimer's disease
    Mary Sano
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA
    CNS Spectr 8:846-53. 2003
  4. ncbi request reprint Noncholinergic treatment options for Alzheimer's disease
    Mary Sano
    Bronx Veterans Medical Research Development, Bronx, NY 10468 3904, USA
    J Clin Psychiatry 64:23-8. 2003
  5. ncbi request reprint The effects of galantamine treatment on caregiver time in Alzheimer's disease
    Mary Sano
    Mount Sinai School of Medicine Veterans Affairs Hospital, Bronx, NY 10468, USA
    Int J Geriatr Psychiatry 18:942-50. 2003
  6. pmc Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease
    Mary Sano
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Alzheimer Dis Assoc Disord 25:122-7. 2011
  7. ncbi request reprint A guide to diagnosis of Alzheimer's disease
    Mary Sano
    Bronx Veterans Administration Hospital, 130 W Kingsbridge Road, Bronx, NY 10468, USA
    CNS Spectr 9:16-9. 2004
  8. ncbi request reprint Economic effect of cholinesterase inhibitor therapy: implications for managed care
    Mary Sano
    Alzheimer Disease Research Center, Mount Sinai School of Medicine, Bronx Veterans Administration Medical Center, Bronx, New York 10468, USA
    Manag Care Interface 17:44-9. 2004
  9. pmc A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
    M Sano
    Mount Sinai School of Medicine, Bronx, NY 10468, USA
    Neurology 77:556-63. 2011
  10. pmc Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials
    Mary Sano
    Mount Sinai School of Medicine, Bronx, NY, USA
    Alzheimer Dis Assoc Disord 20:232-41. 2006

Research Grants

Detail Information

Publications83

  1. ncbi request reprint Schizophrenia in a patient with spinocerebellar ataxia 2: coincidence of two disorders or a neurodegenerative disease presenting with psychosis?
    Matthew Rottnek
    Department of Neurology, James J Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA
    Am J Psychiatry 165:964-7. 2008
  2. pmc Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo
    John W Steele
    Departments of Neurology, Psychiatry and Alzheimer s Disease Research Center, Mount Sinai School of Medicine, New York, NY, 10029, USA
    Mol Neurodegener 4:51. 2009
    ..In the current study, we assessed the effect of acute dosing of latrepirdine on levels of extracellular Abeta using in vitro and in vivo experimental systems...
  3. ncbi request reprint Current concepts in the prevention of Alzheimer's disease
    Mary Sano
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA
    CNS Spectr 8:846-53. 2003
    ..Information can also be gathered when dementia evaluation is added to ongoing studies. As results from these studies becoming available, we will be able to refine our approach to managing this disease...
  4. ncbi request reprint Noncholinergic treatment options for Alzheimer's disease
    Mary Sano
    Bronx Veterans Medical Research Development, Bronx, NY 10468 3904, USA
    J Clin Psychiatry 64:23-8. 2003
    ..The cost of these studies is high, but the potential benefit of delay or prevention of disease is the valuable goal...
  5. ncbi request reprint The effects of galantamine treatment on caregiver time in Alzheimer's disease
    Mary Sano
    Mount Sinai School of Medicine Veterans Affairs Hospital, Bronx, NY 10468, USA
    Int J Geriatr Psychiatry 18:942-50. 2003
    ..The aim of the study was to determine whether the clinical benefits of galantamine for patients with Alzheimer's disease lead to benefits for caregivers...
  6. pmc Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease
    Mary Sano
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Alzheimer Dis Assoc Disord 25:122-7. 2011
    ..To determine if the addition of delayed recall (DR) assessment adds sensitivity to the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-cog) in clinical trials in mild cognitive impairment (MCI) and Alzheimer Disease (AD)...
  7. ncbi request reprint A guide to diagnosis of Alzheimer's disease
    Mary Sano
    Bronx Veterans Administration Hospital, 130 W Kingsbridge Road, Bronx, NY 10468, USA
    CNS Spectr 9:16-9. 2004
    ..The issues of cognitive screening in old age and age-associated memory impairment will be discussed. Similarly, the pitfalls and advantages of routine cognitive screening in daily practice will be addressed...
  8. ncbi request reprint Economic effect of cholinesterase inhibitor therapy: implications for managed care
    Mary Sano
    Alzheimer Disease Research Center, Mount Sinai School of Medicine, Bronx Veterans Administration Medical Center, Bronx, New York 10468, USA
    Manag Care Interface 17:44-9. 2004
    ..The cost savings range from 73 dollars over two years to 3891 dollars over one year, depending on the type of study, drug evaluated, and economic model employed in the evaluation...
  9. pmc A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
    M Sano
    Mount Sinai School of Medicine, Bronx, NY 10468, USA
    Neurology 77:556-63. 2011
    ....
  10. pmc Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials
    Mary Sano
    Mount Sinai School of Medicine, Bronx, NY, USA
    Alzheimer Dis Assoc Disord 20:232-41. 2006
    ....
  11. doi request reprint ICAD 2010: Detection may hold the key to treatment. International Conference on Alzheimer Disease (ICAD) 2010 Honolulu, HI, USA, 10–15 July 2010
    Mary Sano
    James J Peters Veterans Administrations Medical Center, Department of Psychiatry, Mount Sinai School of Medicine, 130 W Kingsbridge Rd, Code 150 Rm 1F01, Bronx, NY 10468, USA
    Expert Rev Neurother 10:1659-61. 2010
    ..Key themes of this year's conference included validation of biomarkers, drug development, the value of screening for cognitive loss and dementia and the proposal of a new criteria for Alzheimer's disease...
  12. pmc ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly
    Mary Sano
    Mount Sinai School of Medicine, James J Peters VAMC, Bronx, NY 10468, USA
    Alzheimer Dis Assoc Disord 20:S191-202. 2006
    ..In addition, the loss that relates to the subjects' own time as they transition through cognitive impairment is not well documented...
  13. ncbi request reprint Neuropsychological testing in the diagnosis of dementia
    Mary Sano
    Alzheimer Disease Research Center of Mount Sinai School of Medicine, New York, NY, USA
    J Geriatr Psychiatry Neurol 19:155-9. 2006
    ....
  14. ncbi request reprint Undertreatment of patients with Alzheimer's disease in an elderly United States population
    Mary Sano
    Mount Sinai School of Medicine, Bronx Veterans Medical Research Center, 130 W Kingsbridge Rd, Bronx, NY 10468, USA
    Alzheimers Dement 1:136-44. 2005
    ....
  15. ncbi request reprint Preventing Alzheimer's disease : separating fact from fiction
    Mary Sano
    The Alzheimer Disease Research Center of Mount Sinai School of Medicine, New York, New York, USA
    CNS Drugs 22:887-902. 2008
    ..We review the evidence from completed trials, support for ongoing studies and propose directions for future research...
  16. pmc A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics
    Mary Sano
    Mount Sinai School of Medicine, Department of Psychiatry, New York, NY, USA
    Clin Trials 5:523-33. 2008
    ..Observational studies and small clinical trials suggested that hormone replacement therapy (HRT) decreases risk of cognitive loss and Alzheimer's disease (AD) in postmenopausal women and may have value in primary prevention...
  17. pmc Pilot study to show the feasibility of a multicenter trial of home-based assessment of people over 75 years old
    Mary Sano
    Mount Sinai School of Medicine, New York, USA
    Alzheimer Dis Assoc Disord 24:256-63. 2010
    ..This report describes a pilot study to evaluate feasibility of new home-based assessment technologies applicable to clinical trials for prevention of cognitive loss and Alzheimer disease...
  18. pmc Patient dependence and longitudinal changes in costs of care in Alzheimer's disease
    Carolyn W Zhu
    Geriatric Research, Education, and Clinical Center GRECC, James J Peters VA Medical Center, Bronx, NY, NY 10468, USA
    Dement Geriatr Cogn Disord 26:416-23. 2008
    ..To examine the incremental effect of patients' dependence on others, on cost of medical and nonmedical care, and on informal caregiving hours over time...
  19. ncbi request reprint ADCS Prevention Instrument Project: overview and initial results
    Steven H Ferris
    Alzheimer s Disease Center, New York University School of Medicine, New York, NY 10016, USA
    Alzheimer Dis Assoc Disord 20:S109-23. 2006
    ..Initial results for the experimental instruments and for the book club are reported in separate accompanying articles...
  20. pmc C-reactive protein and familial risk for dementia: a phenotype for successful cognitive aging
    Jeremy M Silverman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, USA
    Neurology 79:1116-23. 2012
    ....
  21. pmc Cardiovascular risk and memory in non-demented elderly women
    Sophia Wang
    Alzheimer Disease Research Center, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Neurobiol Aging 31:1250-3. 2010
    ..To determine whether cardiovascular (CV) risk is associated with subtle memory deficits in non-demented, healthy older women with a family history of Alzheimer disease (AD)...
  22. pmc Cognition in non-demented diabetic older adults
    Sirisha Nandipati
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Curr Aging Sci 5:131-5. 2012
    ..A specific role of diabetes as a risk for cognitive impairment will require longitudinal study...
  23. pmc The effects of patient function and dependence on costs of care in Alzheimer's disease
    Carolyn W Zhu
    Geriatric Research, Education, and Clinical Center, Program of Research on Serious Physical and Mental Illness, James J Peters Veterans Affairs Medical Center, Bronx, New York 10468, USA
    J Am Geriatr Soc 56:1497-503. 2008
    ..To estimate incremental effects of patients' dependence and function on costs of care during the early stages of Alzheimer's disease (AD) and to compare strengths of their relationships with different cost components...
  24. doi request reprint Increased neurofibrillary tangles in patients with Alzheimer disease with comorbid depression
    Michael A Rapp
    Department of Psychiatry, Mount Sinai School of Medicine, New York, USA
    Am J Geriatr Psychiatry 16:168-74. 2008
    ..The authors tested the hypothesis that neuritic plaques and neurofibrillary tangles are more pronounced in the brains of patients with AD with comorbid depression as compared with patients with AD without depression...
  25. pmc Increased presence of cognitive impairment in hemodialysis patients in the absence of neurological events
    James B Post
    Nephrology Division, James J Peters Veterans Affairs Medical Center, Bronx, NY, USA
    Am J Nephrol 35:120-6. 2012
    ..The aim was to compare cognitive function in HD patients with no history of stroke or dementia and well-matched controls. Studies are required to determine the impact of HD and chronic kidney disease-specific risks on CI...
  26. ncbi request reprint Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression
    Michael A Rapp
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Arch Gen Psychiatry 63:161-7. 2006
    ..Although there is increasing evidence that major depression may interact with neuropathological processes in AD, there have been no studies of neuropathological changes in AD as a function of history of major depression...
  27. pmc Home health and informal care utilization and costs over time in Alzheimer's disease
    Carolyn W Zhu
    Geriatric Research, Education, and Clinical Center GRECC, James J Peters VA Medical Center, Bronx, NY 10468, USA
    Home Health Care Serv Q 27:1-20. 2008
    ....
  28. pmc Cognitive performance in community-dwelling English- and Spanish-speaking seniors
    Alex D Federman
    Division of General Internal Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Age Ageing 38:669-75. 2009
    ..to examine the association of language (English vs Spanish), and commonly used measures of memory and word fluency among older adults...
  29. doi request reprint Health-related resource use and costs in elderly adults with and without mild cognitive impairment
    Carolyn W Zhu
    Department of Geriatrics and Palliative Medicine, Alzheimer Disease Research Center, Bronx, NY 10468, USA
    J Am Geriatr Soc 61:396-402. 2013
    ..To assess differences in resource use and cost between older adults with and without mild cognitive impairment (MCI) over time...
  30. pmc Heritability of cognitive functions in families of successful cognitive aging probands from the Central Valley of Costa Rica
    Tiffany A Greenwood
    Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
    J Alzheimers Dis 27:897-907. 2011
    ....
  31. pmc Evaluating cognition in an elderly cohort via telephone assessment
    Effie M Mitsis
    Alzheimer s Disease Research Center, Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Int J Geriatr Psychiatry 25:531-9. 2010
    ..We examined the feasibility, and its comparability to in-person assessment, of a telephone administered battery of established neuropsychological measures of cognitive functioning in healthy, elderly women...
  32. pmc Comparison of costs of care between patients with Alzheimer's disease and dementia with Lewy bodies
    Carolyn W Zhu
    Geriatric Research, Education, and Clinical Center and Program of Research on Serious Physical and Mental Illness, Targeted Research Enhancement Program, James J Peters VA Medical Center, Bronx, NY, USA
    Alzheimers Dement 4:280-4. 2008
    ..This cross-sectional analysis of baseline data from the Predictors II Study took place in three university-based AD centers in the U.S...
  33. doi request reprint Impact of APOE epsilon4 on the cognitive performance of a sample of non-demented Puerto Rican nonagenarians
    JOSE R CARRION-BARALT
    Mount Sinai School of Medicine, Department of Psychiatry, New York, NY, USA
    J Alzheimers Dis 18:533-40. 2009
    ..In conclusion, the results of this study suggest that, among these Puerto Rican non-demented nonagenarians, being an APOE epsilon4 allele carrier is associated with better cognition...
  34. pmc Assessment and familial aggregation of psychosis in Alzheimer's disease from the National Institute on Aging Late Onset Alzheimer's Disease Family Study
    Robert A Sweet
    Department of Psychiatry, University of Pittsburgh, Biomedical Science Tower, Rm W 1645, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA
    Brain 133:1155-62. 2010
    ..Future studies should examine the linkage and association of psychosis with genetic variation within these families...
  35. pmc Utilization of antihypertensives, antidepressants, antipsychotics, and hormones in Alzheimer disease
    Carolyn W Zhu
    Geriatric Research, Education, and Clinical Center GRECC and Health Services Research and Development HSR and D Center for Study of Health Care across Systems and Sites of Care, James J Peters VA Medical Center, Bronx, New York, NY 10468, USA
    Alzheimer Dis Assoc Disord 25:144-8. 2011
    ..Findings suggest accurate modeling of the Alzheimer disease treatment paradigm for certain subgroups of patients should include antihypertensives and antipsychotics in addition to cholinesterase inhibitors and memantine...
  36. pmc Synaptic protein deficits are associated with dementia irrespective of extreme old age
    Michal Schnaider Beeri
    Mount Sinai School of Medicine, Department of Psychiatry, New York, NY 10029, USA
    Neurobiol Aging 33:1125.e1-8. 2012
    ....
  37. ncbi request reprint Relationship of neuropsychological performance to functional status in nursing home residents and community-dwelling older adults
    Michael A Rapp
    Dept of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Pl, Box 1240, New York, NY 10029 6574, USA
    Am J Geriatr Psychiatry 13:450-9. 2005
    ..The authors examined the association between neuropsychological tests of executive functioning and episodic memory and functional disability in nursing home residents versus community-dwelling older adults...
  38. pmc Cognitive profile of chronic kidney disease and hemodialysis patients without dementia
    James B Post
    Nephrology Division, James J Peters Veterans Affairs Medical Center, Bronx, N Y 10468, USA
    Nephron Clin Pract 116:c247-55. 2010
    ..We aimed to assess cognitive function in CKD and HD patients with no history of stroke or dementia, in order to identify and characterize early cognitive deficits...
  39. pmc The neuropsychological performance of nondemented Puerto Rican nonagenarians
    JOSE R CARRION-BARALT
    Department of Psychiatry, Mount Sinai School of Medicine, New York, N Y, USA
    Dement Geriatr Cogn Disord 27:353-60. 2009
    ..This study sought to evaluate the neuropsychological performance of nondemented nonagenarians residing in Puerto Rico and to compare their results with those of a similar English-speaking sample from New York...
  40. doi request reprint Detection of mild cognitive impairment and early stage dementia with an audio-recorded cognitive scale
    Margaret C Sewell
    The Alzheimer s Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA
    Int Psychogeriatr 25:1325-33. 2013
    ....
  41. pmc Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease
    Carolyn W Zhu
    Department of Geriatrics and Palliative Medicine, Mount Sinai School of Medicine, New York, NY, USA Electronic address
    Alzheimers Dement 9:733-40. 2013
    ....
  42. pmc Profiles of Alzheimer's disease-related pathology in an aging urban population sample in India
    Dushyant P Purohit
    Department of Pathology, Mount Sinai School of Medicine, New York, NY, USA
    J Alzheimers Dis 24:187-96. 2011
    ....
  43. pmc Cognitive performance in hypotensive persons with spinal cord injury
    Adejoke B Jegede
    VA Rehabilitation Research and Development Service, Center of Excellence for the Medical Consequences of Spinal Cord Injury, James J Peters VA Medical Center, Rm 1E 02 130 West Kingsbridge Rd, Bronx, NY, 10468, USA
    Clin Auton Res 20:3-9. 2010
    ..Several investigations in the non-SCI population have noted a relationship between chronic hypotension and deficits in memory, attention and processing speed and delayed reaction times...
  44. pmc Clinical characteristics and longitudinal changes of informal cost of Alzheimer's disease in the community
    Carolyn W Zhu
    Geriatric Research, Education, and Clinical Center and Program of Research on Serious Physical and Mental Illness, James J Peters Department of Veterans Affairs Medical Center, Bronx, New York 10468, USA
    J Am Geriatr Soc 54:1596-602. 2006
    ..Each additional point on the BDRS increased informal caregiving costs 5.4%. Average annual informal cost was estimated at $25,381 per patient, increasing from $20,589 at baseline to $43,030 in Year 4...
  45. pmc Health literacy and cognitive performance in older adults
    Alex D Federman
    Division of General Internal Medicine Development, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Am Geriatr Soc 57:1475-80. 2009
    ..To study the relationship between health literacy and memory and verbal fluency in older adults...
  46. pmc Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals
    Michal Schnaider Beeri
    Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY 10029, United States
    Mech Ageing Dev 132:583-7. 2011
    ..Serum levels are increased in diabetes and aging. We examined the relationship between serum methylglyoxal derivatives (sMG), and cognitive decline, in 267 non-demented elderly...
  47. ncbi request reprint Cross-domain variability of cognitive performance in very old nursing home residents and community dwellers: relationship to functional status
    Michael A Rapp
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Gerontology 51:206-12. 2005
    ..Recent evidence suggests that cross-domain variability in cognition may be related to subsequent cognitive decline beyond mean performance levels in cognitive tasks...
  48. ncbi request reprint Women's cognitive and affective health and neuropsychiatry
    Amy Aloysi
    The Alzheimer Disease Research Center, Mount Sinai School of Medicine, New York, NY, USA
    Mt Sinai J Med 73:967-75. 2006
    ....
  49. ncbi request reprint Neuropsychological differences between late-onset and recurrent geriatric major depression
    Michael A Rapp
    Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Pl, Box 1230, New York, NY 10029, USA
    Am J Psychiatry 162:691-8. 2005
    ..The purpose of this study was to explore differences in neuropsychological function, symptoms, and cardiovascular comorbidity between patients with late-onset and recurrent geriatric major depression...
  50. ncbi request reprint Prevention of Alzheimer's disease: where we stand
    Mary Sano
    Department of Neurology, College of Physicians and Surgeons of Columbia University, 630 W 168th Street, Box 16, New York, NY 10032, USA
    Curr Neurol Neurosci Rep 2:392-9. 2002
    ..This review begins by examining the progress that has been made in this disease. Current efforts to develop prevention strategies are described and possible agents for future evaluation are discussed...
  51. pmc Economic considerations in the management of Alzheimer's disease
    Carolyn W Zhu
    Geriatric Research, Education, and Clinical Center GRECC and Program of Research on Serious Physical and Mental Illness, Targeted Research Enhancement Program TREP, Bronx VA Medical Center, Bronx, NY 10468 USA
    Clin Interv Aging 1:143-54. 2006
    ..Continued home care for patients under pharmacological treatment may reduce caregiver burden, healthcare costs, and ultimately improve patients' and caregivers' QoL...
  52. doi request reprint Age, gender, and education are associated with cognitive performance in an older Israeli sample with type 2 diabetes
    Elizabeth Guerrero-Berroa
    Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA James J Peters Veterans Affairs Medical Center, Bronx, NY, USA
    Int J Geriatr Psychiatry 29:299-309. 2014
    ..To evaluate the relationships of age, education, and gender with performance on neuropsychological tests in a cognitively intact, older Israeli sample with type 2 diabetes (T2D)...
  53. doi request reprint Evidence against a role for rare ADAM10 mutations in sporadic Alzheimer disease
    Guiqing Cai
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Neurobiol Aging 33:416-417.e3. 2012
    ....
  54. pmc Use of Medicare and Department of Veterans Affairs health care by veterans with dementia: a longitudinal analysis
    Carolyn W Zhu
    Research Enhancement Award Program and Geriatric Research, Health Services Research and Development Service, James J Peters Veterans Affairs Medical Center, Bronx, New York 10468, USA
    J Am Geriatr Soc 57:1908-14. 2009
    ..Efforts to coordinate care between VA and Medicare providers are necessary to ensure that patients receive high-quality care, especially patients with multiple comorbidities...
  55. ncbi request reprint The impact of nutrition on cognition in the elderly
    Kathleen Van Dyk
    Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Neurochem Res 32:893-904. 2007
    ..Clinical trials have explored these mechanisms through supplementation studies with minimal benefits being observed. Continuing work to hone the mechanisms and refine our knowledge of dietary benefits is described...
  56. doi request reprint A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition
    Effie M Mitsis
    Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L, Levy Place, Box 1230, New York, NY 10029, USA
    Mol Neurodegener 9:10. 2014
    ..Most importantly, amyloid imaging may improve certainty of etiology in situations where the differential diagnosis cannot be resolved on the basis of standard clinical and laboratory criteria...
  57. pmc Functional neural correlates of attentional deficits in amnestic mild cognitive impairment
    Nicholas T Van Dam
    Department of Psychology, Queens College, City University of New York, Flushing, New York, United States of America
    PLoS ONE 8:e54035. 2013
    ..Although based on a small number of patients, our findings suggest that deficits of attention, especially the executive control of attention, may significantly contribute to the behavioral and cognitive deficits of aMCI...
  58. pmc Current treatment and recent clinical research in Alzheimer's disease
    Judith Neugroschl
    Mount Sinai School of Medicine, New York, NY, USA
    Mt Sinai J Med 77:3-16. 2010
    ..A brief review of the current Food and Drug Administration-approved treatments is included...
  59. ncbi request reprint An update on treatment and prevention strategies for Alzheimer's disease
    Judith Neugroschl
    James J Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA
    Curr Neurol Neurosci Rep 9:368-76. 2009
    ..An update on results from pharmacologic and nonpharmacologic prevention trials is provided...
  60. ncbi request reprint No long-term effect of behavioral treatment on psychotropic drug use for agitation in Alzheimer's disease patients
    Myron F Weiner
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, USA
    J Geriatr Psychiatry Neurol 15:95-8. 2002
    ..0 for subjects in each drug arm or placebo arm versus BMTs. We concluded that teaching caregivers BMTs did not diminish long-term prescription of psychotropic drugs...
  61. ncbi request reprint Cardiac risk factors and potential treatments in Alzheimer's disease
    Christine Bergmann
    Alzheimer Disease Research Center of Mount Sinai School of Medicine, NYC, James J Peters VAMC, Bronx, NY 10468, USA
    Neurol Res 28:595-604. 2006
    ..Based on these data, we propose that early interventions at reducing these cardiovascular risk factors may have an impact on future incidence and prevalence of cognitive deficits of many etiologies including Alzheimer's disease...
  62. ncbi request reprint Do dietary antioxidants prevent Alzheimer's disease?
    Mary Sano
    Taub Institute for Alzheimer s Disease Research and the Gertrude H Sergievsky Center, Department of Neurology, College of Physicians and Surgeons of Columbia University, New York, NY, USA
    Lancet Neurol 1:342. 2002
  63. pmc Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: implication of additional loci
    Joseph H Lee
    Gertrude H Sergievsky Center, Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
    Arch Neurol 65:1518-26. 2008
    ..To identify putative genetic loci related to the risk of late-onset Alzheimer disease (LOAD)...
  64. doi request reprint Protean phenotypic features of the A3243G mitochondrial DNA mutation
    Petra Kaufmann
    Department of Neurology, The Neurological Institute, Columbia University Medical Center, New York, NY 10032, USA
    Arch Neurol 66:85-91. 2009
    ....
  65. pmc High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial
    Paul S Aisen
    Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
    JAMA 300:1774-83. 2008
    ..Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline...
  66. ncbi request reprint Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial
    Paul S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
    JAMA 289:2819-26. 2003
    ....
  67. ncbi request reprint Ischemic stroke and depression
    David W Desmond
    Department of Neurology, SUNY Downstate Medical Center, Brooklyn, New York 11203, USA
    J Int Neuropsychol Soc 9:429-39. 2003
    ..SIGH-D item analyses suggested that a reliance on nonsomatic rather than somatic symptoms would result in the most accurate diagnoses of depression after ischemic stroke...
  68. ncbi request reprint A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease
    Paul S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20007, USA
    Am J Geriatr Psychiatry 11:246-9. 2003
    ..Authors determined the impact of high-dose vitamin supplements on plasma homocysteine levels in patients with Alzheimer disease (AD)...
  69. ncbi request reprint Cognitive effects of estrogens in women with cardiac disease: what we do not know
    Mary Sano
    Am J Med 113:612-3. 2002
  70. ncbi request reprint Incidence of dementia after ischemic stroke: results of a longitudinal study
    David W Desmond
    Department of Neurology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    Stroke 33:2254-60. 2002
    ..We conducted the present study to investigate the incidence and clinical predictors of dementia after ischemic stroke...
  71. ncbi request reprint Mortality in patients with dementia after ischemic stroke
    David W Desmond
    Department of Neurology, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA
    Neurology 59:537-43. 2002
    ..The authors investigated dementia as a predictor of long-term survival among patients with ischemic stroke...
  72. ncbi request reprint Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale
    Richard S E Keefe
    Neurocognitive Assessment Unit, Duke University Medical Center, Durham, NC 27710, USA
    Schizophr Bull 29:45-55. 2003
    ....
  73. doi request reprint Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX, USA
    Lancet 372:207-15. 2008
    ..More effective treatments are needed. We assessed the safety, tolerability, and efficacy of dimebon in the treatment of patients with mild-to-moderate Alzheimer's disease...
  74. ncbi request reprint Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials
    Michael Grundman
    Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
    Arch Neurol 61:59-66. 2004
    ..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD...
  75. ncbi request reprint Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future
    Warachal E Faison
    Alzheimer s Research and Clinical Programs, Neurosciences Department, Medical University of South Carolina, Charleston, South Carolina 29406, USA
    Int Psychogeriatr 19:539-58. 2007
    ..for AD to answer two questions: (1) what are the challenges to diagnose and treat AD across different ethnic groups, and (2) are there differences in response to pharmacologic interventions for AD across these different ethnic groups?..
  76. ncbi request reprint ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials
    Douglas Galasko
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0624, USA
    Alzheimer Dis Assoc Disord 20:S152-69. 2006
    ..ADL change during a trial could trigger detailed evaluation or serve as an outcome measure. A brief, easily administered, and reliable ADL rating scale would assist prevention studies...
  77. ncbi request reprint ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trials
    David P Salmon
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093 0948, USA
    Alzheimer Dis Assoc Disord 20:S139-46. 2006
    ....
  78. ncbi request reprint Vitamin E and donepezil for the treatment of mild cognitive impairment
    Ronald C Petersen
    Mayo Clinic College of Medicine, Rochester, Minn, USA
    N Engl J Med 352:2379-88. 2005
    ..Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer's disease...
  79. ncbi request reprint ADCS Prevention Instrument Project: quality of life assessment (QOL)
    Marian B Patterson
    Case Western Reserve University, Cleveland, OH, USA
    Alzheimer Dis Assoc Disord 20:S179-90. 2006
    ..We conclude that the QOL scores at baseline show sufficient range and reliability to suggest they will have utility in tracking QOL through conversion to dementia...
  80. ncbi request reprint Estrogen levels do not correlate with improvement in cognition
    Leon J Thal
    Department of Neurosciences, University of California, San Diego, School of Medicine, 9500 Gilman Dr, La Jolla, CA 92093, USA
    Arch Neurol 60:209-12. 2003
    ..To investigate whether an association exists between estradiol and estrone levels and measures of cognitive functioning in women with Alzheimer disease (AD) treated with conjugated equine estrogen (Premarin; Wyeth-Ayerst, Philadelphia, Pa)...
  81. pmc A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium
    Zaven S Khachaturian
    Alzheimers Dement 4:156-63. 2008
  82. ncbi request reprint Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis
    Miguel A Pappolla
    University of South Alabama, Mobile 36617, USA
    Free Radic Biol Med 33:173-81. 2002
    ..Experimental data links cholesterol and oxidative stress with some neurodegenerative aspects of AD...
  83. ncbi request reprint Reliability of monitoring the clinical dementia rating in multicenter clinical trials
    Kimberly A Schafer
    Department of Neurosciences, University of California, San Diego, CA, USA
    Alzheimer Dis Assoc Disord 18:219-22. 2004
    ..An abbreviated version, with formal monitoring for consistency across sites and raters, is currently used in the Alzheimer's Disease Cooperative Study (ADCS)...

Research Grants12

  1. Alzheimer's Disease Prevention Trial with Estrogens
    Mary Sano; Fiscal Year: 2007
    ..This trial may represent the very last chance to determine if estrogen can have a benefit in dementia prevention and memory protection. ..
  2. ALZHEIMERS DISEASE PREVENTION TRIAL WITH ESTROGENS
    Mary Sano; Fiscal Year: 2002
    ..Participants who become demented will be informed of standard-of-care treatment and will continue to be followed at annual intervals for the length of the study. ..